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Increased expression of the C-C chemokine monocyte chemoattractant protein-1 (MCP-1) in mesothelial cells in response to high
glucose concentrations and/or high osmolality plays a crucial role in the development of peritoneal ﬁbrosis during continuous
ambulatory peritoneal dialysis (CAPD). Recent studies suggest that in kidney cells osmolality-induced MCP-1 upregulation is
mediated by the osmosensitive transcription factor, nuclear factor of activated T cells 5 (NFAT5). The present study addressed
the question of whether activation of NFAT5 by hyperosmolality, as present in PD ﬂuids, contributes to MCP-1 expression in the
mesothelial cell line Met5A. Hyperosmolality, induced by addition of glucose, NaCl, or mannitol to the growth medium, increased
NFAT5 activity and stimulated MCP-1 expression in Met5A cells. siRNA-mediated knockdown of NFAT5 attenuated osmolality-
induced MCP-1 upregulation substantially. Hyperosmolality also induced activation of nuclear factor-κB( N F - κB). Accordingly,
pharmacological inhibition of NF-κB signiﬁcantly decreased osmolality-induced MCP-1 expression. Taken together, these results
indicate that high osmolalities activate the transcription factor NFAT5 in mesothelial cells. NFAT5 in turn upregulates MCP-1,
likely in combination with NF-κB, and thus may participate in the development of peritoneal ﬁbrosis during CAPD.
1.Introduction
Peritoneal dialysis (PD) is a well-established and eﬀective
renal replacement therapy that is employed regularly in pa-
tients suﬀering from end-stage chronic kidney disease. The
long-time eﬃciency of PD is limited by the bio-incompati-
bility of the currently used PD ﬂuids (PDF) [1]. The latter
induces severe pathophysiological changes in the peritoneal
membrane, such as ﬁbrosis and angiogenesis, which eventu-
ally are responsible for the functional failure of continuous
ambulatory peritoneal dialysis (CAPD) [2, 3]. Conventional
PDFs are characterized by high concentrations of glucose
degradation products (GDPs), an unphysiological low pH,
and high osmolalities [4]. In the last two decades signiﬁcant
eﬀorts have been undertaken to improve the biocompatibil-
ityofPDFsbyminimizingtheformationofGDPduringheat
sterilization [2, 4] and by establishing a more physiological
pH [5]. Although the physicochemical properties have been
improved,eﬃcientultraﬁltrationacrosstheperitonealmem-
brane requires supraphysiological osmolalities in the range
of 380–510mosm/kgH2O, depending on the respective PDF.
Accordingly, peritoneal mesothelial cells are exposed to local
osmotic stress for several hours during PD.
The assumption that local osmotic stress contributes to
the bio-incompatibility of PDFs is supported by the notion
that even with the use of novel PDF, with a nearly physiolog-
ical pH and low content of GDP, the mesothelium produces
large amounts of established markers of peritoneal damage
[6]. Proinﬂammatory mediators such as TGF-β1o rM C P -
1 are synthesized in peritoneal mesothelial cells not only in
responsetoglucosebutalsoinresponsetoosmotic stress[7].
The exposure of mesothelial cells to local osmotic stress
during PD suggests an activation of the osmosensitive tran-
scription factor NFAT5 (nuclear factor of activated T cells 5;
also known as TonEBP or OREBP) in peritoneal mesothelial
cells. NFAT5 was originally identiﬁed in collecting duct cells
of the renal medulla [8], which are exposed to interstitial
osmolalities severalfold higher compared to plasma osmolal-
ity (up to 1.200mosm/kgH2O) during antidiuresis. In renal2 Mediators of Inﬂammation
cells NFAT5 regulates the expression of various genes
necessaryforaneﬃcienturinaryconcentration,forexample,
AQP-2 or UT-A, as well as genes required for the adap-
tation to high osmolalities, for example, aldose reductase
or HSP70 [9]. NFAT5-regulated genes contain tonicity en-
hancer (TonE) elements in their promoter region, to which
upon activation NFAT5 binds and stimulates the transcrip-
tional machinery.
Recent studies suggest that under various pathophysio-
logical conditions NFAT5 is activated by local osmotic stress
and stimulates the expression of proinﬂammatory cytokines
[10, 11], probably in cooperation with NF-κB[ 12]. In
particular, upregulation of MCP-1 in renal tubular epithelial
cells exposed to osmotic stress has been shown to be NFAT5
dependent [12, 13]. The C-C chemokine MCP-1 is a potent
chemoattractant for circulating T cells and macrophages/
monocytes [14] and plays a key role in the recruitment of
these cells to the peritoneal cavity [15]. Besides its chemoat-
tractant activity, MCP-1 stimulates expression of adhesion
molecules and proinﬂammatory cytokines in monocytes
[16] and induces calcium ﬂux and the respiratory burst [17].
In ﬁbroblasts, MCP-1 may increase synthesis of collagen
and TGF-β1[ 18], another key factor for the remodelling of
peritoneal tissue. Pathophysiological upregulation of MCP-1
expression contributes to ﬁbrotic lesions in the lung [19], the
liver [20], and the kidney [21]. Since MCP-1 is also involved
in the development of peritoneal damage [22–27], the aim
of the present study was to determine whether activation of
NFAT5 in response to osmotic stress, as present during PD,
contributes to enhanced expression of MCP-1 in peritoneal
mesothelial cells.
2. Methods
2.1. Materials. The NF-κB inhibitor Bay 11-7082 was ob-
tained from Sigma (Deisenhofen, Germany). Anti-NFAT5
antibody weas from Santa Cruz Biotechnology (Santa Cruz,
CA,USA);anti-actinantibodywasfromSigma;anti-p65and
anti-phospho-p65(Ser536)andhorseradishperoxidase-con-
jugated anti-rabbit IgG were purchased from Cell Signaling
(Beverly, MA, USA); anti-histone H1 was from Millipore
(Billerica, MA, USA). Unless otherwise indicated, other re-
agents were purchased from Biomol (Hamburg, Germany),
Biozol (Eching, Germany), Carl Roth (Karlsruhe, Germany),
or Sigma.
2.2. Cell Culture. Immortalized human mesothelial cells
(Met5A, ATCC CRL-9444) were cultured in M199 culture
medium supplemented with 4mM 4-(2-hydroxyethyl)-1-
piperazineethanesulfonic acid (HEPES), with 10% fetal bo-
vineserum(Biochrom,Berlin,Germany),100units/mLpen-
icillin, and 100μg/mL streptomycin (Invitrogen, Karlsruhe,
Germany) at 37◦C in a humidiﬁed atmosphere (95% air/5%
CO2). Cells were grown in 24-well plates to conﬂuency. For
experiments, medium osmolality was increased by addition
of glucose or, as osmotic controls, NaCl or mannitol.
2.3. qRT-PCR Analysis. For determination of MCP-1 and β-
Actin mRNA expression levels, the total RNA from Met5A
cells was prepared by adding TRIFAST Reagent (PEQLAB,
Erlangen, Germany). The primers (Metabion, Martinsried,
Germany) used in this experiment were MCP-1 fw: 5 -
AGT CTC TGC CGC CCT TCT-3 ;M C P - 1rev: 5 -GTG
ACT GGG GCA TTG ATT G-3 ;a c t i nfw: 5 -CCA ACC
GCG AGA AGA TGA-3 ;a c t i nrev: 5 -CCA GAG GCG
TAC AGG GAT AG-3 . Experiments were carried out on
a Roche LightCycler 480, using the SensiMix SYBR One-
Step Kit (Bioline, Luckenwalde, Germany) according to the
manufacturer’s recommendations. Speciﬁcity of PCR prod-
uct formation was conﬁrmed by monitoring melting point
analysis and by agarose gel electrophoresis.
2.4. Immunoblot Analysis. Aliquots (5–30μg protein) were
subjected to 10% sodium dodecyl sulfate polyacrylamide
gel electrophoresis (SDS-PAGE) and blotted onto nitrocel-
lulose membranes (Amersham Pharmacia Biotech, Bucking-
hamshire, UK). Nonspeciﬁc binding sites were blocked with
5% nonfat dry milk in PBS containing 0.1% Tween-20 (PBS-
T) at room temperature for 1h. Samples were incubated
with primary antibodies in PBS-T containing 5% nonfat dry
milk over night at 4◦C. Subsequently, the blots were washed
3 times with PBS-T for 5min each, and the membranes
thenincubatedwithappropriatesecondaryantibodyatroom
temperaturefor1hinPBS-Tcontaining5%nonfatdrymilk.
After washing with PBS-T 3 times for 5min each, immuno-
complexes were visualized by enhanced chemiluminescence
(Pierce, Rockford, IL, USA).
2.5.PreparationofCytosolicandNuclearExtracts. Subcellular
extracts were prepared with the ProteoJET cytoplasmic and
nuclear protein extraction kit (Fermentas,St. Leon-Rot, Ger-
many) according to the manufacturer’s recommendations,
with broad speciﬁcity protease inhibitor cocktail (Sigma)
added at 1:100 (v/v).
2.6. MCP-1 Measurement. Concentration of MCP-1 in the
cell culture supernatant was determined using a speciﬁc
ELISA kit (PeproTech, Hamburg, Germany) according to the
manufacturer’s recommendations.
2.7. Reporter Gene Assays. Activation of transcription factors
NF A T5orNF-κBinresponsetohyperosmolalitywasassessed
using the secreted alkaline phosphatase system (SEAP), with
reporter constructs in which the SEAP open reading frame is
under control of the respective transacting elements. pNF-
κB-SEAP (Clontech, Heidelberg, Germany) contains four
copiesoftheκBresponseelement;pSEAP-TonEcontainstwo
TonE sites [28]. For transfection, Met5A cells were grown to
∼80% conﬂuency, trypsinated, washed in PBS, and 106 cells
were ﬁnally resuspended in 200μL modiﬁed HBS electropo-
ration buﬀe r( 0 . 5 %H E P E S ,1 %g l u c o s e ,0 . 5 %F i c o l l ,5m M
NaCl, 135mM KCl, 2mM MgCl2, pH 7.4) together with
10μg of the respective reporter vector. Electroporation was
performed using a Gene Pulser X cell electroporation system
(Bio-Rad, Hercules, CA, USA) at 150V and 950μF( e x p o -
nential decay pulse) in a 2mm cuvette, and the cells were
subsequently seeded immediately in 96-well plates. After
growing to conﬂuency, the cells were treated as indicated andMediators of Inﬂammation 3
SEAP activity in the medium determined as described before
[29].
2.8. NFAT5 Transactivation Assay. NFAT5 transactivation
activity was determined using the GAL4 binary assay as
initially described by Ferraris et al. [30]. pGAL4-TonEBP-
TAD contains the yeast GAL4 DNA-binding domain fused
in frame to the transactivation domain (TAD) of NFAT5
(amino acids 548-1531; kindly provided by Dr. J. Ferraris,
National Institutes of Health, Bethesda, MD, USA). pFR-
SEAP (Agilent Technologies, Santa Clara, CA, USA) contains
ﬁve tandem repeats of the GAL4 binding site upstream of a
minimal promoter and the SEAP gene. Brieﬂy, 106 cells were
electroporated with 10μgp G A L 4 - T o n E B P - T A Da n d1 0 μg
pFR-SEAP as described above. After growing to conﬂuency,
the cells were treated as indicated and SEAP activity in the
medium determined as described before [29].
2.9. NFAT5 Knockdown. Accell SMARTpool siRNA con-
struct for knockdown of NFAT5 or Accell nontargeting
siRNA (no. 2) were obtained from Thermo Fisher Scientiﬁc
(Epsom, UK). Knockdown in Met5A cells was performed
accordingtothemanufacturer’sinstructions.Theconcentra-
tion of siRNA constructs was 1μM in Accell delivery med-
ium,containing2%FCS.Cellswereincubatedfor5days,and
knock-down eﬃciency was determined by qRT-PCR and by
western blot analysis.
2.10. Statistical Analyses. Data are expressed as means ±
SEM. The signiﬁcance of diﬀerences between the means was
assessed by Student’s t-test. P<0.05 was regarded as signif-
icant. All experiments were performed at least three times,
and representative results are shown.
3. Results
3.1. Osmolality-Induced Upregulation of MCP-1 Expression in
Met5A Cells. The eﬀect of medium osmolality on MCP-1
secretion of Met5A cells was tested by measurement of MCP-
1 concentration in the cell culture supernatants. The cells
were incubated in isosmotic (300mosm/kgH2O) or hyper-
osmotic (400mosm/kgH2O) medium. The medium osmo-
lality was elevated by the addition of glucose. To distinguish
between glucose-speciﬁc eﬀects and osmolality-induced ef-
fects, mannitol or NaCl was used as osmotic controls. Sam-
ples of cell culture supernatant were taken at various times
between 2 and 24h. Under isosmotic conditions constitutive
MCP-1 secretion could be observed: MCP-1 concentration
in the cell culture supernatant rose from 25 ± 8pg/mLafter
2h to 220 ± 43pg/mL after 24h (Figure 1(a)). This con-
stitutive MCP-1 secretion was signiﬁcantly enhanced under
hyperosmotic conditions. The strongest eﬀect was observed
when medium osmolality was elevated by addition of
glucose: MCP-1 concentration reached 760 ± 26pg/mL after
24h. The eﬀects of mannitol (480 ± 67pg/mL after 24h)
and NaCl (390 ± 36pg/mL after 24h) were less pronounced
than that of glucose but were still signiﬁcantly increased
compared to the isosmotic control.
An osmolality-induced increase of MCP-1 expression
was also observed at the mRNA level (Figure 1(b)). Sur-
prisingly, at all tested times NaCl (rather than glucose) had
the strongest eﬀect on MCP-1 mRNA abundance, while on
the protein level glucose had the stronger eﬀect (see above),
probably indicating that glucose, and not osmolality per se,
also stimulates posttranscriptional and/or posttranslational
mechanisms, thus further enhancing MCP-1 secretion.
3.2. Osmolality-Induced Activation of NFAT5 in Met5A Cells.
In kidney cells, hyperosmolality stimulates overall NFAT5
activity by (i) increased NFAT5 expression, (ii) increased
NFAT5 translocation into the nucleus, and (iii) activation
of the NFAT5 transactivation domain. Accordingly, hyperos-
molality elevated NFAT5 expression also in Met5A cells, at
both the protein and mRNA levels (Figures 2(a)–2(c)). The
most prominent eﬀect was observed when medium osmolal-
ity was raised by addition of NaCl; glucose and mannitol also
caused a robust increase of NFAT5 abundance. Additionally,
hyperosmolality increased translocation of NFAT5 from the
cytoplasm into the nucleus (Figures 2(d) and 2(e))a n d
activity of the NFAT5 transactivation domain (Figure 2(f)).
Activation of NFAT5 in Met5A cells by hyperosmolality
was assayed using a TonE-driven reporter vector. Medium
osmolalities were elevated to 325–550mosm/kgH2Ob y
addition of glucose, mannitol, or NaCl, and Met5A cells,
transfected transiently with the reporter construct, were
incubated for 24h. Raising the medium osmolality increased
NFAT5 activity approximately 2-3 fold (Figure 2(g)). For
glucose and mannitol, NFAT5 activity reached a maximum
at a ﬁnal osmolality of 400mosm/kgH2O, for NaCl at 450
mosm/kgH2O. At even higher osmolalities, NFAT5 activity
declined.
3.3. Osmolality-Induced MCP-1 Upregulation Is Decreased
by NFAT5 Knockdown. To evaluate the role of NFAT5 in
osmolality-induced MCP-1 expression, NFAT5 was knocked
down using a siRNA approach. Knock-down eﬃciency, as
tested by immunoblotting (Figure 3(a)), was at ∼80% com-
pared with control cells transfected with a scrambled siRNA.
As expected, hyperosmolality, induced either by glucose
or NaCl addition, signiﬁcantly increased MCP-1 both in the
cell culture supernatant (Figure 3(b)) and at the mRNA level
(Figure 3(c)) of control cells. Knockdown of NFAT5 largely
attenuatedosmolality-inducedincreaseinMCP-1expression
(Figures 3(b) and 3(c)), indicating a central role for NFAT5
in this process.
3.4. Role of NF-κB in Osmolality-Induced MCP-1 Expression.
Another transcription factor probably involved in upregula-
tion of MCP-1 during hyperosmotic stress is NF-κB[ 27]. In
Met5A cells transfected transiently with a κB-driven reporter
vector, hyperosmolality, induced by addition of NaCl or glu-
cose, signiﬁcantly increased reporter activity (Figure 4(a)).
Accordingly, phosphorylation of the p65 subunit was en-
hancedsigniﬁcantlyundertheseconditions(Figure 4(b)), in-
dicating that hyperosmolality activates NF-κB. Next, NF-κB
in Met5A cells was inhibited by treatment with the pharma-
cological inhibitor Bay 11-7082. NF-κB inhibition not only4 Mediators of Inﬂammation
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Figure 1: Osmolality-induced MCP-1 expression. (a) For determination of MCP-1 secretion, conﬂuent Met5A cells were incubated in
isosmotic medium (gray column; 300mosm/kgH2O) or were exposed to hyperosmotic medium (black column; 400mosm/kgH2O).
Medium osmolality was elevated by addition of glucose, NaCl, or mannitol as indicated. At the indicated times, medium samples were
collected and the concentration of MCP-1 in the cell culture supernatant determined by ELISA as described in Section 2. Means ± SEM
for n = 4 per point; ∗P<0.05 versus isosmotic control. (b) For determination of MCP-1 transcription, conﬂuent Met5A cells remained
in isosmotic medium (gray column; 300mosm/kgH2O) or were exposed to hyperosmotic medium (black column; 400mosm/kgH2O).
Medium osmolality was elevated by addition of glucose, NaCl, or mannitol as indicated. At the indicated time points, RNA was extracted
fromthecellsandtheabundanceofMCP-1mRNAtranscriptwasdeterminedbyqRT-PCRasdescribedin Section 2.R elati v eMCP -1mRN A
abundance was normalized to that of β-actin to correct for diﬀerences in RNA input. Data are means ± SEM for n = 4 per point; ∗P<0.05
versus isosmotic control.Mediators of Inﬂammation 5
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Figure 2: Expression and activation of NFAT5 in Met5A cells. Met5A cells were kept in isosmotic medium (300mosm/kgH2O) or were
e x p o s e dt oh y p e r o s m o t i cm e d i u m( 4 0 0m o s m / k gH 2O). Medium osmolality was elevated by addition of glucose, NaCl, or mannitol as
indicated. (a) Cells were incubated for 24h and subsequently processed for immunoblotting as described in Section 2.T od e m o n s t r a t e
comparable protein loading, the blots were also probed for actin. A representative blot from 3 independent experiments is shown. (b)
Relative NFAT5 protein abundance was quantiﬁed by densitometric analysis of immunoblots and normalized to that of actin to correct for
diﬀerences in protein loading. Means ± SEM for n = 3; ∗P<0.05 versus isosmotic control. (c) Cells were incubated for 16h. Thereafter,
RNA was extracted and the abundance of MCP-1 mRNA transcript determined by qRT-PCR as described in Section 2.R e l a t i v eM C P - 1
mRNA abundance was normalized to that of β-actin to correct for diﬀerences in RNA input. Means ± SEM for n = 3 per point; ∗P<0.05
versus isosmotic control. (d) Cells were incubated for 1h, and subsequently cytoplasmic and nuclear extracts prepared and processed for
immunoblotting as described in Section 2. To demonstrate purity of extracts and comparable protein loading, the blots were also probed
for histone H1 and actin. A representative blot from 4 independent experiments is shown. (e) Relative NFAT5 nuclear versus cytoplasmic
abundance was quantiﬁed by densitometric analysis of immunoblots. Means ± SEM for n = 3; ∗P<0.05 versus isosmotic control. (f)
Activity of the transactivation domain of NFAT5 during osmotic stress. Met5A cells were cotransfected with a vector encoding the fusion
protein GAL4dbd-TonEBP-TAD (amino acids 548-1541 of NFAT5 fused to the yeast GAL4 DNA binding domain) together with the reporter
vectorpFR-SEAP.Cellswerekeptinisosmoticmedium(300mosm/kgH2O)orwereexposedtohyperosmoticmedium(400mosm/kgH2O).
After 48h, SEAP activity was measured as described in Section 2. Means ± SEM for n = 3; ∗P<0.05 versus isosmotic control. (g) Met5A
cells were transiently transfected with a reporter construct in which the SEAP gene is under control of two TonE sites. Cells were kept in
isosmotic (300mosm/kg H2O) medium or were exposed to hyperosmotic medium, with osmolalities between 325 and 550mosm/kgH2O
as indicated. After 24h, SEAP activity was measured as described in Section 2. Means ± SEM for n = 4; ∗P<0.05 versus isosmotic control.
abolished MCP-1 expression under hyperosmotic conditions
but also signiﬁcantly reduced constitutive MCP-1 expression
under isosmotic conditions (Figures 4(c) and 4(d)).
4. Discussion
Although the biocompatibility of PD solutions has been
improved during the recent years by the use of bicarbonate
rather than lactate buﬀers and by limiting excessive GDP
formation, hyperosmolality of PDF is required for eﬀective
ultraﬁltration into the dialysate. The latter is in most cases
achieved by the addition of glucose to osmolalities of 380–
510mosm/kgH2O. Such high glucose concentrations induce
the expression of proinﬂammatory mediators in mesothelial
cells that in turn promote serious long-term complications
such as progressive peritoneal ﬁbrosis or even sclerosingMediators of Inﬂammation 7
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Figure 3: NFAT5-knockdown attenuates osmolality-induced MCP-1 expression. Met5A cells were transfected with siRNA constructs for
NFAT5 or with nontargeting siRNA as control as indicated. Cells were kept in isosmotic medium (gray column; 300mosm/kgH2O) or were
exposed to hyperosmotic medium (black column; 400mosm/kgH2O). Medium osmolality was elevated by addition of glucose or NaCl as
indicated, and cells were incubated for 24h. (a) To demonstrate eﬃciency of NFAT5 knockdown, cells were processed for immunoblotting
as described in Section 2. To demonstrate comparable protein loading, the blots were also probed for actin. (b) For determination of MCP-1
secretion, medium samples were collected and the concentration of MCP-1 in the cell culture supernatant was determined by ELISA as
described in Section 2. Means ± SEM for n = 4 per point; ∗P<0.05. (c) For determination of MCP-1 transcription, RNA was extracted
fromthecellsandtheabundanceofMCP-1mRNAtranscriptwasdeterminedbyqRT-PCRasdescribedin Section 2.R elati v eMCP -1mRN A
abundance was normalized to that of β-actin to correct for diﬀerences in RNA input. Means ± SEM for n = 4 per point; ∗P<0.05.
peritonitis. Particularly, the expression of TGF-β1a n dM C P -
1 is induced in mesothelial cells in response to high glucose
concentrations or high osmolality, respectively [7, 27]. The
C-C chemokine MCP-1 recruits monocytes and CD8 T
lymphocytestotheperitonealcavity,wherethesecellssecrete
a variety of cytokines and growth factors, which induce or
aggravatedamageoftheperitonealmembrane.Inthepresent
study, we provide evidence that the osmosensitive tran-
scription factor NFAT5 contributes to osmolality-induced
MCP-1 expression in the mesothelial cell line Met5A. To
distinguish between glucose-speciﬁc eﬀects and osmolality-
induced eﬀects, experiments were carried out not only with
glucose but also with NaCl or mannitol as osmotic controls.
Generally, activation of NFAT5 and upregulation of MCP-
1 were induced by all three agents, indicating that MCP-1
expression is largely induced in response to hyperosmotic
stress.However,somediﬀerencesbetweenNaCl-inducedand
glucose-induced MCP-1 expression could be observed and
are discussed below. siRNA-mediated knockdown of NFAT5
attenuated the osmolality-induced activation of MCP-1
expression, clearly demonstrating the important role for
NFAT5 in this context. The regulation of MCP-1 expression
under hyperosmotic conditions by NFAT5 has been recently
described in rat and human kidney cells [12, 13]. At least
one TonE element at position −199bp to −186bp upstream
from the transcriptional start site has been identiﬁed in the
MCP-1 regulatory region, to which NFAT5 binds in response
to osmotic stress [13]. Activation of NFAT5 under these
conditions probably depends on the MAP kinases p38 and
ERK1/2 [12, 13].
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Figure 4: Role of NF-κB in osmolality-induced MCP-1 expression. (a) Activation of NF-κB by osmolality. Met5A cells were transiently
transfected with a reporter construct in which the SEAP gene is under control of κB sites. Cells were kept in isosmotic (300mosm/kgH2O)
medium or were exposed to hyperosmotic medium (400mosm/kgH2O). Medium osmolality was elevated by addition of glucose or NaCl.
After 24h, SEAP activity was measured as described in Section 2. Means ± SEM for n = 4; #P<0.05 versus isosmotic control. (b)
Phosphorylation of the p65 subunit by osmolality. Met5A cells were kept in isosmotic medium (300mosm/kgH2O) or were exposed to
hyperosmoticmedium(400mosm/kgH2O).MediumosmolalitywaselevatedbyadditionofglucoseorNaCl.After16h,cellswereprocessed
for immunoblotting as described in Section 2. Abundance of phosphorylated p65 or whole p65 was tested using speciﬁc antibodies. A
representative blot of three independent experiments is shown. (c) MCP-1 secretion. Met5A cells were preincubated for 1h with the NF-κB
inhibitor Bay 11-7082 (5μM) or with vehicle DMSO only. Cells were kept in isosmotic (gray column; 300mosm/kgH2O) medium or were
exposed to hyperosmotic medium (black column; 400mosm/kgH2O). Medium osmolality was elevated by addition of glucose or NaCl.
After 24h, medium samples were collected and the concentration of MCP-1 in the cell culture supernatant was determined by ELISA as
described in Section 2. Means ± SEM for n = 4 per point; ∗P<0.05. (d) MCP-1 transcription. Met5A cells were preincubated for 1h with
theNF-κBinhibitorBay11-7082(5μM)orwithvehicleDMSOonly.Cellswerekeptinisosmotic(graycolumn;300mosm/kgH2O)medium
or were exposed to hyperosmotic medium (black column; 400mosm/kgH2O). Medium osmolality was elevated by addition of glucose or
NaCl.After24h,RNAwasextractedfromthecells andtheabundanceofMCP-1mRNAtranscriptwasdeterminedbyqRT-PCRasdescribed
in Section 2. Relative MCP-1 mRNA abundance was normalized to that of β-actin to correct for diﬀerences in RNA input. Means ± SEM for
n = 4 per point; ∗P<0.05.Mediators of Inﬂammation 9
NFAT5 expression probably due to stabilization of NFAT5
mRNA [31], by increased activity of the transactivation
domain within the c-terminal portion of NFAT5 [30, 32],
and by enhanced translocation from the cytoplasm to the
nucleus [33,34].Accordingly,hyperosmolalityinducedasig-
niﬁcantupregulationofNFAT5expression,increasednuclear
translocation,andanincreasedactivityofthetransactivation
domain also in Met5A cells.
We demonstrated activation of NFAT5 activity in re-
sponse to hyperosmolality in Met5A cells using a TonE-
drivenreporterconstruct.Generally,theinductionofNFAT5
activity by hyperosmolality in Met5A cells is relatively weak
compared to kidney cells. With the same TonE-driven re-
porter construct, we observed an approximately 20-fold
induction of NFAT5 activity in kidney cells [28], while in
Met5A cells an approximately 2-fold induction occurred.
Notably, maximal NFAT5 activation could be observed at
about 400–450mosm/kgH2O and declined rapidly at higher
osmolalities, while in kidney cells maximal NFAT5 activation
is achieved at osmolalities of >500mosm/kgH2O. In kidney
cells, the nonreceptor tyrosine kinase focal adhesion kinase
(FAK) is a positive regulator of NFAT5 activity under hy-
perosmotic conditions [35]; in mesothelial cells, high os-
molalities, and especially high glucose concentrations, in-
hibitFAK[36],whichmayaccountforthedecreasingNFAT5
activity at osmolalities >450mosm/kgH2O. Furthermore,
the decreased NFAT5 activity may reﬂect a general decrease
in cellular activity and perhaps cellular damage of mesothe-
lial cells in response to high osmolalities [37]. In contrast,
kidney cells have evolved eﬀective mechanisms to maintain
cellular activity even during hyperosmolality [38].
Met5A cells showed signiﬁcant constitutive MCP-1
expression under isosmotic conditions. This basal expression
appears to be largely independent of NFAT5, as NFAT5
knockdown had marginal eﬀects on MCP-1 abundance at
both the mRNA and protein levels under isosmotic condi-
tions. In contrast, the pharmacological NF-κB inhibitor Bay
11-7082 signiﬁcantly reduced not only hyperosmotic-
induced MCP-1 expression but also basal expression under
isosmotic conditions, indicating that basal NF-κBa c t i v i t y
under isosmotic conditions is necessary for basal MCP-1
expression. Involvement of NF-κBi nr e g u l a t i o no fo s m o l a -
lity-induced MCP-1 expression in mesothelial cells has been
shown previously [27]. In Met5A cells, hyperosmolality
activated a κB-driven reporter vector, especially in response
to NaCl but also, to a lesser extent, in response to glucose.
Accordingly, hyperosmolality induced phosphorylation of
the p65 subunit of NF-κB. A cooperation of NFAT5 with NF-
κB during osmolality-induced expression of cytokines has
been already demonstrated in kidney cells [12]. In this study,
the authors propose a model in which direct interaction of
NFAT5 with the p65 subunit of NF-κB increases binding
of NF-κBt oκB sites around −2470bp and −2440bp in
the promoter region of MCP-1 and enhances NF-κBt r a n -
scriptional activity under hypertonic conditions. However,
the identiﬁcation of a TonE site in the MCP-1 promoter
region provides evidence that NFAT5 may stimulate MCP-
1 expression by two diﬀerent mechanisms: ﬁrst, by direct
binding to the TonE site around −190bp and activation of
the transcriptional machinery; second, by interaction with
NF-κB to enhance DNA binding and transcriptional activity
of NF-κB.
Interestingly, there were some diﬀerences in MCP-1 up-
regulation depending on whether medium osmolality was
elevatedbyNaClorglucose.AdditionofNaCltothemedium
had a stronger eﬀect on NFAT5 abundance and activity
and also on NF-κB activity. Accordingly, MCP-1 mRNA
abundance was more robustly induced by addition of NaCl
compared to glucose. In contrast, the abundance of MCP-
1 protein in cell culture supernatants was signiﬁcantly more
enhanced by glucose than by NaCl, indicating that post-
transcriptional and/or posttranslational mechanisms further
stimulate MCP-1 accumulation in the presence of glucose. A
possible mechanism which may account for this observation
couldbeproteinglycosylation.MCP-1canbemodiﬁedbyO-
glycosylation and sialylation [39, 40], and this glycosylation
enhances MCP-1 protein stability [41]. Since high glucose
concentrations can enhance protein O-glycosylation [42,
43], it is conceivable that enhanced MCP-1 O-glycosylation
contributes to the observed increased MCP-1 concentrations
incellculturesupernatantsundertheseconditions.However,
since O-glycosylation of MCP-1 was not assessed in this
study, this possibility remains to be established.
As mentioned above, hyperosmolality activated NFAT5
in mesothelial cells, regardless of whether glucose, NaCl, or
mannitol was used as the osmotic agent. This is not surpris-
ing since NFAT5 activation by these compounds has been
shown before in various cell lines [13, 44, 45]. Several studies
indicate that replacement of glucose as osmotic agent by
icodextrin or amino acids may improve biocompatibility of
PD ﬂuids [46–48]. For future studies, it may be interesting to
test the eﬀects of icodextrin- or L-carnitine-induced hyper-
osmolality on NFAT5 activation and MCP-1 expression in
mesothelial cells.
In T cells, NFAT5 has also been identiﬁed as a positive
regulator for the expression of the proinﬂammatory cytoki-
nesTNF-αandlymphotoxin-β (LT-β)inr esponsetoosmotic
stress [49]. Since especially TNF-α is an important mediator
of pathological alterations of the peritoneal membrane
during CAPD [50], we also analyzed osmolality-induced
expression of TNF-α and LT-β in Met5A cells. However, we
could not detect signiﬁcant expression of TNF-α or LT-β
either under isosmotic or hyperosmotic conditions (data not
shown). This is in accordance with the assumption that,
during CAPD, TNF-α is synthesized preferentially by mono-
cytes/macrophages [51] rather than mesothelial cells.
The gene encoding the chaperone HSP70 is another
NFAT5-regulated gene [52]. Upregulation of HSP70 in
response to PDF has been demonstrated in in vitro and in
vivomodelsofPD[53,54]andconfersincreasedresistanceto
PDF toxicity to mesothelial cells [55]. Knockdown of NFAT5
in Met5A cells also decreased HSP70 expression (data not
shown), indicating that hyperosmolality-induced NFAT5
activity may also have an important role for cytoprotection
of mesothelial cells during CAPD.10 Mediators of Inﬂammation
5. Conclusions
Taken together, the present study indicates that the tran-
scription factor NFAT5 is activated in response to high
osmolalities in mesothelial cells and that this activation
contributes to increased expression of MCP-1, probably in
collaboration with NF-κB.
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